Knight Therapeutics Inc (TSE:GUD) – Research analysts at National Bank Financial boosted their FY2016 earnings estimates for Knight Therapeutics in a research report issued on Thursday. National Bank Financial analyst L. Aghazarian now expects that the brokerage will post earnings per share of $0.14 for the year, up from their previous estimate of $0.12.

A number of other brokerages have also commented on GUD. Bloom Burton reiterated an “accumulate” rating on shares of Knight Therapeutics in a report on Thursday, November 10th. Scotiabank lowered their target price on Knight Therapeutics from C$10.00 to C$9.50 and set an “outperform” rating on the stock in a research note on Friday, November 11th. CIBC boosted their target price on Knight Therapeutics from C$9.50 to C$9.80 in a research note on Friday, November 11th. Finally, TD Securities boosted their target price on Knight Therapeutics from C$10.00 to C$11.00 and gave the company a “buy” rating in a research note on Friday, November 11th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Knight Therapeutics has a consensus rating of “Buy” and a consensus price target of C$9.83.

About Knight Therapeutics

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.